Extended Data Fig. 3: Dependence of dapagliflozin-induced somatostatin secretion on cAMP.

a-b, Somatostatin secretion from (a) mouse and (b) human islets at 4 mM glucose in the presence and absence of forskolin and dapagliflozin as indicated. Data are based on 4 experiments from 8 mice and n=4 experiments from 4 human donors run in at least quadruplicate (n>16). Statistical significances were determined by one-way ANOVA followed by Tukey’s post hoc. Data have been normalized to somatostatin secretion at 4 mM glucose. *p<0.05; ***p<0.001; ns=not significant (p=0.78). c-d, Insulin (c) and somatostatin secretion (d) at 1 and 20 mM glucose in the absence and presence of the insulin receptor antagonist S961 as indicated. Data are based on n=10 experiments using islets from 4 mice. Statistical significances were determined by one-way ANOVA followed by Tukey’s post hoc. Data have been normalized to secretion at 1 mM glucose. ***p<0.001 vs 1 mM glucose; ††p<0.01 vs 20mM glucose. All data are represented as mean ± SEM.